(Q36613901)

15 August 2017

1 reference

title

Tiagabine in anxiety disorders (English)

1 reference

15 August 2017

Thomas L Schwartz

1

1 reference

PubMed ID

17020423

15 August 2017

Nikhil Nihalani

series ordinal

2

1 reference

PubMed ID

17020423

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

7

1 reference

15 August 2017

14

1 reference

15 August 2017

1977-1987

1 reference

Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

GABAA receptor gamma 2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Antiepileptic drugs in the treatment of anxiety disorders: role in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Treatment of social phobia with gabapentin: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Tiagabine for the treatment of anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

An open-label study of tiagabine as augmentation therapy for anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Seizure activity and off-label use of tiagabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

GABA-ergic drugs: exit stage left, enter stage right

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

Early coadministration of clonazepam with sertraline for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1977

10.1517/14656566.7.14.1977

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17020423